Impact Factor
3.37
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.29
273 total citations
h5-index
22
h5 depth signal
Cited share
82.8%
72 of 87
Total citations
273
Citation footprint
Metric signal
2.80
External metric anchor
Self-citation
0.0%
0 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Egypt
191
India
129
China
27
Iran
25
United States
22
Citing Fields of Research
Oncology
144
Breast Cancer
89
Cancer & Development
57
Immunology
43
Liver & Colon Cancer
40
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
676
Articles tracked across the journal lifetime
Indexed publication set
87
72 cited publications
Last 12 months
92
7.7 publications/month
Open access share
100.0%
92 OA publications in the last year
Leading citing country
Egypt
191 citing publications
Leading citing field
Oncology
144 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v17n1, Mar. 2005-
v17n1, Mar. 2005-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Breast Cancer
Immunology
Noncoding RNA
Cancer & Development
Lung Cancer
Reproductive Health
Issuing & Sponsoring Bodies
Contributor
Maʻhad al-Qawmī lil-Awrām (Egypt)
Broad Categories
Neoplasms
Hematology
Breast Cancer
Immunology
Liver & Colon Cancer
Musculoskeletal & Nerve Cancer
Urology
Noncoding RNA
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1186/s43046-026-00419-x
Open DOI
Ferroptosis in cancer: molecular mechanisms, tumour microenvironment, therapeutic resistance, and clinical translation
Ferroptosis is a distinct form of regulated cell death driven by iron-dependent lipid peroxidation and oxidative membrane damage, and it differs fundamentally from apoptosis, necroptosis, and pyroptosis in its molecular mechanisms and ex...
02
DOI 10.1186/s43046-026-00402-6
Open DOI
Association of XRCC6 -61 C > G and XRCC7 6721G > T polymorphisms with susceptibility to pediatric acute lymphoblastic leukemia
Background: Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children. The XRCC6 and XRCC7 genes play a key role in the nonhomologous end-joining (NHEJ) repair process and may influence susceptibility to ALL. The aim...
03
DOI 10.1186/s43046-026-00418-y
Open DOI
Cancer nanomedicine and RNA/Lipid nanoparticle platforms in oncology: developmental evolution, translational barriers, and precision-therapy opportunities
Nanomedicine has become an important translational platform in oncology by enabling altered pharmacokinetics, controlled exposure, reduced systemic toxicity, intracellular delivery of nucleic acids, and improved handling of complex thera...
04
DOI 10.1186/s43046-026-00417-z
Open DOI
Prediction of treatment response and survival in patients with advanced hepatocellular carcinoma receiving sorafenib: pretreatment prognostic scores
Introduction: Sorafenib is currently among the recommended first-line medications for patients with advanced hepatocellular carcinoma (HCC); however, response to sorafenib remains unpredictable despite efforts to define prognosis. This s...
05
DOI 10.1186/s43046-026-00415-1
Open DOI
Next-generation CAR-T cell therapy against cancer: precision engineering, programmable immunity, and emerging clinical frontiers
While chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies, there are significant hurdles to ove
06
DOI 10.1186/s43046-026-00408-0
Open DOI
Male breast cancer in Arab populations: a systematic review of molecular, genetic, and clinicopathologic characteristics
Background: Male breast cancer (MBC) accounts for less than 1% of all breast cancer cases, yet its incidence is increasing worldwide. Research on MBC remains limited, particularly in Arab populations, where molecular and genetic characte...
07
DOI 10.1186/s43046-026-00411-5
Open DOI
Recent advances in hormone-based biopharmaceuticals for cancer therapy
Hormone-dependent cancers, particularly estrogen receptor-positive breast cancer and androgen receptor-driven prostate cancer, contribute substantially to global cancer-related morbidity and mortality. Endocrine therapy has long been the...
08
DOI 10.1186/s43046-026-00412-4
Open DOI
Epigallocatechin-3-Gallate, the green tea polyphenol suppresses expression of CD31 and VEGFR2 and enhances the chemotherapeutic potential of irinotecan in AOM/DSS model of colorectal cancer in mice
Background: Conventional chemotherapeutic treatment of colorectal cancer causes adverse effects such as severe diarrhoea, mucositis and hepatotoxicity. This study aimed to investigate the anti-carcinogenic potential of epigallocatechin-3...
09
10
DOI 10.1186/s43046-026-00414-2
Open DOI
Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non–small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials
Background: The optimal first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for EGFR-mutant advanced non–small cell lung cancer (NSCLC) remains uncertain due to the availability of multiple generations of T...
Bibliographical & Catalog Notes
Description based on: Vol. 13, no. 2 (June 2001); title from cover.
Print issues ceased with v. 21 (2009)?
Also issued online.
v. 1, no. 1 (1995)20050628 Notice not published Printed on acid-free paper